Welcome to LookChem.com Sign In|Join Free
  • or
2-(R)-2-(4,7,10-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododec-1-yl)-pentanedioic acid, 1-tert-butyl-5-benzyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

817562-89-3

Post Buying Request

817562-89-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

817562-89-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 817562-89-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,1,7,5,6 and 2 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 817562-89:
(8*8)+(7*1)+(6*7)+(5*5)+(4*6)+(3*2)+(2*8)+(1*9)=193
193 % 10 = 3
So 817562-89-3 is a valid CAS Registry Number.

817562-89-3Downstream Products

817562-89-3Relevant academic research and scientific papers

Trivalent Gd-DOTA reagents for modification of proteins

Fisher, Martin J.,Williamson, Daniel J.,Burslem, George M.,Plante, Jeffrey P.,Manfield, Iain W.,Tiede, Christian,Ault, James R.,Stockley, Peter G.,Plein, Sven,Maqbool, Azhar,Tomlinson, Darren C.,Foster, Richard,Warriner, Stuart L.,Bon, Robin S.

, p. 96194 - 96200 (2015/11/24)

The development of novel protein-targeted MRI contrast agents crucially depends on the ability to derivatise suitable targeting moieties with a high payload of relaxation enhancer (e.g., gadolinium(III) complexes such as Gd-DOTA), without losing affinity

Development of a multigram asymmetric synthesis of 2-(R)-2-(4,7,10-tris tert-butylcarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)-pentanedioic acid, 1-tert-butyl ester, (R)-tert-Bu4-DOTAGA1

Levy, Stuart G.,Jacques, Vincent,Zhou, Kevin Li,Kalogeropoulos, Shirley,Schumacher, Kelly,Amedio, John C.,Scherer, Jonathan E.,Witowski, Steven R.,Lombardy, Richard,Koppetsch, Karsten

experimental part, p. 535 - 542 (2010/04/22)

A process for the multigram asymmetric synthesis of the chiral tetraazamacrocycle 2-(R)-2-(4,7,10-tris tert-butylcarboxymethyl- 1,4,7,10-tetraazacyclododec-1-yl)-pentanedioic acid, 1-tert-butyl ester ((R)-tert-Bu4-DOTAGA, 4) has been devised and demonstrated. The nine-step synthesis features an improved synthesis of 2-(S)-5- oxotetrahydrofuran- 2-carboxylic acid, tert-butyl ester 8, the precursor to the novel alkylating agent (S)-5-benzyl 1-tert-butyl 2-(methylsulfonyloxy) pentanedioate 12, which was used to introduce an orthogonally protected chiral glutarate arm to the 1,4,7,10-tetraazacyclododecane (cyclen) nucleus in high optical purity. Cyclen derivative (R)-t-Bu4-DOTAGA, 4, a key intermediate for the manufacture of a magnetic resonance imaging (MRI) candidate, was produced with high chemical (≥95%) and optical (ee ≥ 97%) purity. The process developed was successfully applied to the kilogram-scale cGMP synthesis of (R)-t-Bu4-DOTAGA.

Optically pure and enriched isomers of chelating ligands and contrast agents

-

Page/Page column 14; 16; sheet 1; 2, (2008/06/13)

Organic chelating ligands, organic chelating ligand precursors, and metal chelates are disclosed. Methods for synthesizing the same are also described, including methods for preparing optically-enriched or optically-pure compositions of the same.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 817562-89-3